According to recent researches, the combination of SF-constructed percutaneous tumor immune materials and immune checkpoint blockers, such as programmed cell death protein 1 monoclonal antibody (aPD-1) which can enhance T-cell responses and mediate preclinical antitumor activity by blocking the binding of PD-1 on T cell with PD-L1 on cancer cells, may be a new strategy for effectively enhancing tumor immunotherapy. This evidence concerns the gene PDCD1 and cancer.